Literature DB >> 17988908

Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia.

Karen Keeshan1, Olga Shestova, LaShon Ussin, Warren S Pear.   

Abstract

Trib2 is a member of the Trib family of serine/threonine kinase-like proteins (Trib1, Trib2, Trib3). Mice reconstituted with hematopoietic stem cells (HSC) retrovirally expressing Trib2 uniformly developed fatal transplantable acute myelogenous leukemia (AML). Trib2-induced AML was clonal and we sought to identify cooperating genes in Trib2-induced AML. Using Splinkerette PCR techniques, we identified proviral insertion near HoxA9 in a Trib2 monoclonal tumor, which resulted in greatly elevated HoxA9 expression. Mice reconstituted with HSC cotransduced with HoxA9 and Trib2 had accelerated onset of AML compared to either gene alone. These data identify Trib2 and HoxA9 as cooperating genes in AML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988908     DOI: 10.1016/j.bcmd.2007.06.005

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  18 in total

1.  The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease.

Authors:  Sofie Singbrant; Meaghan Wall; Jennifer Moody; Göran Karlsson; Alistair M Chalk; Brian Liddicoat; Megan R Russell; Carl R Walkley; Stefan Karlsson
Journal:  Haematologica       Date:  2014-01-10       Impact factor: 9.941

2.  MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Authors:  Takashi Yokoyama; Mayuka Nakatake; Takeshi Kuwata; Arnaud Couzinet; Ryo Goitsuka; Shuichi Tsutsumi; Hiroyuki Aburatani; Peter J M Valk; Ruud Delwel; Takuro Nakamura
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

3.  TRIB2 regulates the differentiation of MLL-TET1 transduced myeloid progenitor cells.

Authors:  Hyeng-Soo Kim; Seung Hwan Oh; Ju-Heon Kim; Wern-Joo Sohn; Jae-Young Kim; Do-Hyung Kim; Sang-Un Choi; Kwon Moo Park; Zae Young Ryoo; Tae Sung Park; Sanggyu Lee
Journal:  J Mol Med (Berl)       Date:  2018-10-15       Impact factor: 4.599

4.  Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding.

Authors:  Karen Keeshan; Will Bailis; Priya H Dedhia; Maria E Vega; Olga Shestova; Lanwei Xu; Kristin Toscano; Sacha N Uljon; Stephen C Blacklow; Warren S Pear
Journal:  Blood       Date:  2010-08-30       Impact factor: 22.113

5.  Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.

Authors:  Seiko Yoshino; Takashi Yokoyama; Yoshitaka Sunami; Tomoko Takahara; Aya Nakamura; Yukari Yamazaki; Shuichi Tsutsumi; Hiroyuki Aburatani; Takuro Nakamura
Journal:  Blood       Date:  2021-01-07       Impact factor: 22.113

6.  The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

Authors:  C O'Connor; F Lohan; J Campos; E Ohlsson; M Salomè; C Forde; R Artschwager; R M Liskamp; M R Cahill; P A Kiely; B Porse; K Keeshan
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

Review 7.  Notch signaling in pediatric malignancies.

Authors:  Patrick A Zweidler-McKay
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

8.  Kinome-wide functional genomics screen reveals a novel mechanism of TNFα-induced nuclear accumulation of the HIF-1α transcription factor in cancer cells.

Authors:  Angela Schoolmeesters; Daniel D Brown; Yuriy Fedorov
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

9.  Tribbles-2 is a novel regulator of inflammatory activation of monocytes.

Authors:  Katalin Eder; Hongtao Guan; Hye Y Sung; Jon Ward; Adrienn Angyal; Michelle Janas; Gabriella Sarmay; Erno Duda; Martin Turner; Steven K Dower; Sheila E Francis; David C Crossman; Endre Kiss-Toth
Journal:  Int Immunol       Date:  2008-10-24       Impact factor: 4.823

Review 10.  The Critical Role of TRIB2 in Cancer and Therapy Resistance.

Authors:  Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.